Bioventix PLC (LON:BVXP - Get Free Report) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 3,783.15 ($47.68) and traded as high as GBX 3,950 ($49.78). Bioventix shares last traded at GBX 3,885 ($48.96), with a volume of 5,518 shares trading hands.
Bioventix Stock Down 2.5 %
The company's 50 day simple moving average is GBX 3,783.15 and its two-hundred day simple moving average is GBX 4,123.38. The company has a market capitalization of £199.67 million, a price-to-earnings ratio of 2,346.63 and a beta of 0.35.
Bioventix Increases Dividend
The business also recently announced a dividend, which will be paid on Thursday, November 21st. Investors of record on Thursday, November 7th will be paid a GBX 87 ($1.10) dividend. The ex-dividend date of this dividend is Thursday, November 7th. This is a boost from Bioventix's previous dividend of $68.00. This represents a yield of 2.4%. Bioventix's dividend payout ratio (DPR) is 9,693.25%.
Insider Transactions at Bioventix
In other Bioventix news, insider Bruce Hiscock purchased 300 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of GBX 3,330 ($41.97) per share, for a total transaction of £9,990 ($12,589.79). Insiders own 8.02% of the company's stock.
Bioventix Company Profile
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Recommended Stories
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
